Oric Pharmaceuticals: 50,000-Share Rule 144 Notice for 10/06/2025

Rhea-AI Filing Summary

Oric Pharmaceuticals, Inc. filed a Form 144 reporting a proposed sale of 50,000 common shares through J.P. Morgan Securities LLC on 10/06/2025. The filing lists an aggregate market value of $725,000 and shows 97,122,987 shares outstanding, indicating the block represents a small fraction of total outstanding stock. The securities were acquired the same day via a stock option exercise and payment was made in cash. No sales by the same person were reported in the prior three months. The filer certifies they are not aware of undisclosed material adverse information and includes the standard signature attestation under penalty of law.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	50000	725000	97122987	10/06/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/06/2025	Stock Option Exercise	Issuer			50000	10/06/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ORIC's Form 144 report?

It reports a proposed sale of 50,000 common shares with an aggregate market value of $725,000 to be executed on 10/06/2025 via J.P. Morgan Securities LLC.

How were the shares acquired according to the filing?

The filing states the shares were acquired on 10/06/2025 through a stock option exercise and paid for in cash.

Does the filer report other sales in the past three months?

No. The filing indicates "Nothing to Report" for securities sold during the past three months.

How large is the sale relative to ORIC's outstanding shares?

The sale of 50,000 shares is against 97,122,987 outstanding shares, so it represents a small proportion of total shares outstanding.

What attestation does the filer provide in the Form 144?

The filer certifies they do not know of any undisclosed material adverse information about the issuer and includes the standard signature attestation noting legal penalties for false statements.